

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use **RIASTAP**[®] safely and effectively. See full prescribing information for **RIASTAP**.

**RIASTAP, Fibrinogen Concentrate (Human)
Lyophilized Powder for Solution for Intravenous Injection**
Initial U.S. Approval: 2009

-----**RECENT MAJOR CHANGES**-----

Indications and Usage (1) 06/2021
Dosage and Administration (2.2) 07/2020

-----**INDICATIONS AND USAGE**-----

RIASTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. (1)

RIASTAP is not indicated for dysfibrinogenemia.

-----**DOSAGE AND ADMINISTRATION**-----

For intravenous use only.

- Dose (mg/kg body weight) =
[Target level (mg/dL) - measured level (mg/dL)]
1.7 (mg/dL per mg/kg body weight)
- Dose when fibrinogen level is unknown: 70 mg/kg body weight. (2.1)
- Monitoring of patient’s fibrinogen level is recommended during treatment. A target fibrinogen level of 100 mg/dL should be maintained until hemostasis is obtained. (2.1)
- Injection rate should not exceed 5 mL per minute. (2.3)

-----**DOSAGE FORMS AND STRENGTHS**-----

- **RIASTAP** is available as a single-dose vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution. (3)
- The actual fibrinogen potency for each lot is printed on the vial label and carton. (3)

-----**CONTRAINDICATIONS**-----

Known anaphylactic or severe systemic reactions to human plasma-derived products (4)

-----**WARNINGS AND PRECAUTIONS**-----

- Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. (5.1)
- Thrombotic events have been reported in patients receiving **RIASTAP**. Weigh the benefits of administration versus the risks of thrombosis. (5.2)
- Because **RIASTAP** is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. (5.3)

-----**ADVERSE REACTIONS**-----

- The most serious adverse reactions observed are thrombotic episodes (pulmonary embolism, myocardial infarction, deep vein thrombosis) and anaphylactic reactions. (6)
- The most common adverse reactions observed in clinical studies (frequency >1%) were fever and headache. (6)

To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----**USE IN SPECIFIC POPULATIONS**-----

Pediatric: Shorter half-life and faster clearance than in adults has been observed. (8.4)

See **17** for **PATIENT COUNSELING INFORMATION**.

Revised: 6/2021

FULL PRESCRIBING INFORMATION: CONTENTS*

- 1 INDICATIONS AND USAGE**
- 2 DOSAGE AND ADMINISTRATION**
 - 2.1 Treatment of Congenital Fibrinogen Deficiency
 - 2.2 Preparation and Reconstitution
 - 2.3 Administration
- 3 DOSAGE FORMS AND STRENGTHS**
- 4 CONTRAINDICATIONS**
- 5 WARNINGS AND PRECAUTIONS**
 - 5.1 Hypersensitivity Reactions
 - 5.2 Thrombosis
 - 5.3 Transmissible Infectious Agents
- 6 ADVERSE REACTIONS**
 - 6.1 Clinical Trials Experience
 - 6.2 Postmarketing Experience

- 8 USE IN SPECIFIC POPULATIONS**
 - 8.1 Pregnancy
 - 8.2 Lactation
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamic Action
 - 12.3 Pharmacokinetics
- 14 CLINICAL STUDIES**
- 15 REFERENCES**
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
- 17 PATIENT COUNSELING INFORMATION**

* Sections or subsections omitted from the full prescribing information are not listed.

1
2 **FULL PRESCRIBING INFORMATION**

3
4
5 **1 INDICATIONS AND USAGE**

6
7 RIASTAP[®], Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the
8 treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen
9 deficiency, including afibrinogenemia and hypofibrinogenemia.

10
11 Limitation of Use

12 RIASTAP is not indicated for dysfibrinogenemia.

13
14
15 **2 DOSAGE AND ADMINISTRATION**

16
17 **For intravenous use only.**

18
19 **2.1 Treatment of Congenital Fibrinogen Deficiency**

20 RIASTAP dosing, duration of dosing and frequency of administration should be individualized based
21 on the extent of bleeding, laboratory values, and the clinical condition of the patient.

22
23 RIASTAP dose when baseline fibrinogen level is known.

24 Dose should be individually calculated for each patient based on the target plasma fibrinogen level
25 based on the type of bleeding, actual measured plasma fibrinogen level and body weight, using the
26 following formula [see *Clinical Pharmacology (12.3)*]:

$$\frac{[\text{Target level (mg/dL)} - \text{measured level (mg/dL)}]}{1.7 \text{ (mg/dL per mg/kg body weight)}}$$

27
28
29
30 RIASTAP dose when baseline fibrinogen level is not known.

31 If the patient's fibrinogen level is not known, the recommended dose is 70 mg per kg of body weight
32 administered intravenously.

33
34 Monitor patient's fibrinogen level during treatment with RIASTAP. Maintain a target fibrinogen level
35 of 100 mg/dL until hemostasis is obtained.

36
37 **2.2 Preparation and Reconstitution**

38 The procedures below are provided as general guidelines for preparation and reconstitution of
39 RIASTAP.

40
41 Use aseptic technique when preparing and reconstituting RIASTAP.

42
43 Reconstitute RIASTAP at room temperature as follows:

- 44
45 1. Remove the cap from the product vial to expose the central portion of the rubber stopper.
46
47 2. Clean the surface of the rubber stopper with an antiseptic solution and allow it to dry.

48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94

3. Using an appropriate transfer device or syringe, transfer 50 mL of Sterile Water for Injection into the product vial.

4. Gently swirl the product vial to ensure the product is fully dissolved. **Do not shake the vial.**

After reconstitution, the RIASTAP solution should be colorless and clear to slightly opalescent. Inspect visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates. Discard partially used vials.

RIASTAP is stable for 8 hours after reconstitution when stored at 20-25°C; administer within this time period.

Before administration, filter reconstituted RIASTAP solution with a 17-micron filter (not supplied) into an appropriate syringe.

2.3 Administration

Do not mix RIASTAP with other medicinal products or intravenous solutions. Administer through a separate injection site.

Use aseptic technique when administering RIASTAP.

Administer RIASTAP at room temperature by slow intravenous injection at a rate not exceeding 5 mL per minute.

3 DOSAGE FORMS AND STRENGTHS

RIASTAP is available as a single-dose vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution with 50 mL of Sterile Water for Injection.

The actual fibrinogen potency for each lot is printed on the vial label and carton.

4 CONTRAINDICATIONS

RIASTAP is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products.

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Allergic reactions may occur. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension) occur, immediately discontinue administration [see *Patient Counseling Information (17)*]. The treatment required depends on the nature and severity of the reaction.

95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139

5.2 Thrombosis

Thrombosis may occur spontaneously in patients with congenital fibrinogen deficiency with or without the use of fibrinogen replacement therapy.¹ Thromboembolic events have been reported in patients treated with RIASTAP. Weigh the benefits of RIASTAP administration versus the risk of thrombosis. Monitor patients receiving RIASTAP for signs and symptoms of thrombosis [see [Patient Counseling Information \(17\)](#)].

5.3 Transmissible Infectious Agents

Because RIASTAP is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by a process demonstrated to inactivate and/or remove certain viruses during manufacturing [see [Description \(11\)](#)]. Despite these measures, such products may still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products [see [Patient Counseling Information \(17\)](#)]. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring Pharmacovigilance at 1-866-915-6958.

6 ADVERSE REACTIONS

The most serious adverse reactions reported in clinical studies or through postmarketing surveillance following RIASTAP treatment are thromboembolic episodes, including myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis, and allergic-anaphylactic reactions.

The most common adverse reactions observed in more than one subject in clinical trials (frequency >1%) were fever and headache.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.

The safety and efficacy of fibrinogen concentrate (human) for routine prophylaxis, treatment of bleeding or surgery in subjects with congenital fibrinogen deficiency was evaluated in a retrospective, multicenter trial with a prospective one-year follow-up period. Twenty-two subjects between 2 to 78 years with a mean age of 34 years were enrolled, with treatment recorded during the retrospective period from an age of less than 1 year. Thirteen of the 22 (59.1%) subjects were female, 21 (95.5%) subjects were white, and 1 (4.5%) subject Asian [see [Clinical Studies \(14\)](#)].

The adverse reactions reported in the retrospective period were visual impairment, chest discomfort, chest pain, cough, wheezing, flushing, and venous thrombosis of the limb [1 event each] and dyspnea [2 events]. No adverse reactions were found in the prospective period.

140 **6.2 Postmarketing Experience**

141 Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain
142 size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal
143 relationship to product exposure.

144
145 The following adverse reactions, identified by system organ class, have shown a possible causal
146 relationship with RIASTAP.

- 147
148
 - *Allergic-anaphylactic reactions*: anaphylaxis, dyspnea, rash
 - *Cardiovascular*: thromboembolic complications such as myocardial infarction, pulmonary
149 embolism, and deep vein thrombosis [see *Warnings and Precautions (5.2)*]
 - *General/Body as a Whole*: chills, nausea, vomiting

152

153

154 **8 USE IN SPECIFIC POPULATIONS**

155

156 **8.1 Pregnancy**

157 Risk Summary

158 There are no studies of RIASTAP use in pregnant women. Animal reproduction studies have not been
159 conducted with RIASTAP. It is not known whether RIASTAP can cause fetal harm when administered
160 to a pregnant woman or can affect reproduction capacity.. In the U.S. general population, the estimated
161 background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4%
162 and 15-20%, respectively.

163

164 **8.2 Lactation**

165 Risk Summary

166 There is no information regarding the presence of RIASTAP in human milk, its effects on the
167 breastfed infant, or its effects on milk production. The developmental and health benefits of
168 breastfeeding should be considered along with the mother's clinical need for RIASTAP and any potential
169 adverse effects on the breastfed infant from RIASTAP or from the underlying maternal condition.

170

171 **8.4 Pediatric Use**

172 RIASTAP studies have included subjects below the age of 16 years. In the pharmacokinetic study [see
173 *Clinical Pharmacology (12.3)*], 2 children aged 8 and 11 years and 3 adolescents aged 12, 14 and
174 16 years were studied. Subjects <16 years of age (n = 4) had shorter half-life (69.9 ± 8.5 h) and faster
175 clearance (0.7 ± 0.1 mL/h/kg) compared with adults (half-life: 82.3 ± 20.0 h, clearance:
176 0.53 ± 0.1 mL/h/kg). The number of subjects <16 years of age in this study limits statistical
177 interpretation. In study 4003, treatment at an age below 16 years was described for 11 of the 22
178 subjects enrolled in this study. Seven patients were 6 years or younger at first recorded treatment with
179 fibrinogen concentrate (human), starting from an age of <1 year. Fibrinogen concentrate (human) was
180 administered for prophylaxis as well as for treatment of bleeding events and for perioperative use. Ten
181 patients younger than 18 years of age experienced bleeding events; hemostatic efficacy of fibrinogen
182 concentrate (human) was rated as "effective" in all cases. Six patients underwent 7 surgeries and
183 hemostatic efficacy was rated as "effective" in all cases.

184 **8.5 Geriatric Use**

185 The safety and efficacy of RIASTAP in the geriatric population has not been studied. There were an
186 insufficient number of subjects in this age group to determine whether they respond differently from
187 younger subjects.

188
189

190 **11 DESCRIPTION**

191

192 RIASTAP is a sterile, heat-treated, lyophilized fibrinogen (coagulation factor I) concentrate powder
193 manufactured from pooled human plasma.

194

195 Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa. The
196 native molecule is a dimer and consists of three pairs of polypeptide chains ($A\alpha$, $B\beta$ and γ). Fibrinogen
197 is a physiological substrate of three enzymes: thrombin, factor XIIIa, and plasmin.

198

199 Each vial contains 900 to 1300 mg fibrinogen, 400 to 700 mg human albumin, 375 to 660 mg
200 L-arginine hydrochloride, 200 to 350 mg sodium chloride and 50 to 100 mg sodium citrate. Sodium
201 hydroxide and hydrochloric acid may have been used to adjust the pH. The pH of the reconstituted
202 RIASTAP is in a range of 6.5 to 7.5.

203

204 Viral Clearance

205

206 All plasma used in the manufacture of RIASTAP is tested using serological assays for hepatitis B
207 surface antigen and for antibodies to Human Immunodeficiency Virus (HIV)-1/2 and Hepatitis C
208 Virus (HCV). As an additional safety measure, the plasma is tested with Nucleic Acid Testing (NAT)
209 for Hepatitis B Virus (HBV), HCV and HIV-1 and found to be non-reactive (negative). The plasma is
210 also screened for Hepatitis A Virus (HAV) and Human Parvovirus B19 (B19V) by NAT. Only plasma
211 that passed virus screening is used for production, and the limit for B19V in the fractionation pool is
212 set not to exceed 10^4 IU of B19V DNA per mL.

213

214 RIASTAP is manufactured from cryoprecipitate into a glycine precipitate, which is then further
215 purified by multiple precipitation/adsorption steps. The manufacturing process has been demonstrated
216 to reduce the risk of virus transmission in an additive manner: cryoprecipitation, heat treatment (+60°C
217 for 20 hours in an aqueous solution), two subsequent glycine precipitation steps (initial and main
218 glycine precipitation steps), and lyophilization. These steps have been validated independently in a
219 series of in vitro experiments for their capacity to inactivate and/or remove both enveloped and
220 non-enveloped viruses. The results of virus clearance validation studies for RIASTAP manufacturing
221 process are summarized in [Table 1](#).

222
223
224

Table 1. Cumulative (Log₁₀) Virus Reduction Factors for RIASTAP

Manufacturing Step	Virus Reduction Factor (log ₁₀)					
	Enveloped viruses				Non-enveloped viruses	
	HIV*	BVDV†	WNV‡	PRV§	HAV	CPV¶
Cryoprecipitation	n.d.	n.d.	n.d.	1.6	n.d.	1.9
Heat Treatment	≥5.7	≥9.1	≥8.3	5.4	5.9	1.4
Glycine precipitations (two subsequent steps)	3.9	2.1	n.d.	1.8	1.0	1.6
Lyophilization	n.d.	n.d.	n.d.	n.d.	1.7	n.d.
Cumulative virus reduction (log₁₀)	≥9.6	≥11.2	≥8.3	8.8	8.6	4.9

225 Studies using human parvovirus B19, which are considered experimental in nature, have demonstrated a virus reduction factor of ≥4.5
226 log₁₀ by heat treatment

- 227 * HIV, human immunodeficiency virus, a model for HIV-1 and HIV-2
228 † BVDV, bovine viral diarrhea virus, a model for Hepatitis C virus (HCV) and West Nile Virus (WNV)
229 ‡ WNV, West Nile virus
230 § PRV, Pseudorabies virus, a model for large enveloped DNA viruses
231 || HAV, Hepatitis A virus
232 ¶ CPV, canine parvovirus, a model for B19V
233 n.d. not determined

234
235

12 CLINICAL PHARMACOLOGY

236
237

12.1 Mechanism of Action

239 During the coagulation process, thrombin cleaves the Aα and Bβ chains releasing fibrinopeptides A
240 and B (FPA and FPB, respectively).² FPA is separated rapidly and the remaining molecule is a soluble
241 fibrin monomer (fibrin I). The slower removal of FPB results in formation of fibrin II that is capable of
242 polymerization that occurs by aggregation of fibrin monomers.² The resulting fibrin is stabilized in the
243 presence of calcium ions and by activated factor XIII, which acts as a transglutaminase.

244 Factor XIIIa-induced cross-linking of fibrin polymers renders the fibrin clot more elastic and more
245 resistant to fibrinolysis.³ Cross-linked fibrin is the end result of the coagulation cascade, and provides
246 tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.

247

12.2 Pharmacodynamic Action

249 Administration of RIASTAP to patients with congenital fibrinogen deficiency replaces missing or low
250 levels of coagulation factor. Normal levels are in the range of 200 to 450 mg/dL.⁴

251

12.3 Pharmacokinetics

A prospective, open label, uncontrolled, multicenter pharmacokinetic study was conducted in 5 females and 9 males with congenital fibrinogen deficiency (afibrinogenemia), ranging in age from 8 to 61 years (2 children, 3 adolescents, 9 adults). Each subject received a single intravenous dose of 70 mg/kg RIASTAP. Blood samples were collected to determine fibrinogen activity at baseline and up to 14 days after infusion. The pharmacokinetic parameters of RIASTAP are summarized in Table 2.

No statistically relevant difference in fibrinogen activity was observed between males and females. Subjects <16 years of age (n=4) had shorter half-life (69.9 ± 8.54 h) and faster clearance (0.73 ± 0.14 mL/h/kg) compared with subjects ≥ 16 years of age (half-life of 82.3 ± 20.04 h and clearance of 0.53 ± 0.07 mL/h/kg). The number of subjects <16 years of age in this study limits statistical interpretation.

The incremental in vivo recovery (IVR) was determined from levels obtained up to 4 hours post-infusion. The median incremental IVR was 1.7 mg/dL (range 1.30 – 2.73 mg/dL) increase per mg/kg. The median in vivo recovery indicates that a dose of 70 mg/kg will increase fibrinogen plasma concentration in patients by approximately 120 mg/dL.

The pharmacokinetic analysis using fibrinogen antigen data (ELISA) was concordant with the fibrinogen activity (Clauss assay).

Table 2. Pharmacokinetic Parameters (n=14) for Fibrinogen Activity

Parameters	Mean \pm SD (range)
Half-life [h]	78.7 ± 18.13 (55.73-117.26)
C _{max} [mg/dL]	140 ± 27 (100-210)
AUC for dose of 70 mg/kg [mg*h/mL]	124.3 ± 24.16 (81.73-156.40)
Clearance [mL/h/kg]	0.59 ± 0.13 (0.45-0.86)
Mean residence time [h]	92.8 ± 20.11 (66.14-126.44)
Volume of distribution at steady state [mL/kg]	52.7 ± 7.48 (36.22-67.67)

h: hours

14 CLINICAL STUDIES

The efficacy of RIASTAP is based on maximum clot firmness, a measure of clot structural integrity that reflects the underlying effectiveness of the fibrinogen present to form a fibrin clot. A pharmacokinetic study evaluated single-dose PK [see *Clinical Pharmacology (12.3)*] and maximum clot firmness (MCF) in subjects with afibrinogenemia. MCF was determined by thromboelastometry (ROTEM) testing and was used to demonstrate functional activity of replacement fibrinogen when a fixed dose of RIASTAP was administered. Clot firmness is a functional parameter that depends on activation of coagulation, fibrinogen content of the sample and polymerization/crosslinking of the fibrin network.

Thromboelastometry has been shown to be a functional marker for assessment of fibrinogen content and for effects of fibrinogen supplementation on clinical efficacy.⁵

289 For each subject, MCF was determined before (baseline) and one hour after single dose administration
290 of RIASTAP. RIASTAP was found to be effective in increasing clot firmness in subjects with
291 congenital fibrinogen deficiency (afibrinogenemia) as measured by thromboelastometry. The study
292 results demonstrated that MCF values were significantly higher after administration of RIASTAP than
293 at baseline (see Table 3). Mean change from pre-infusion to 1 hour post-infusion was 8.9 mm in the
294 primary analysis (9.9 mm for subjects <16years old and 8.5 mm for subjects ≥16 to <65 years old).
295 Mean change in MCF values closely approximated levels expected from adding known amounts of
296 fibrinogen to plasma in vitro.⁶

297
298 **Table 3. MCF [mm] (ITT population)**
299

Time point	n	Mean ± SD	Median (range)
Pre-infusion	13	0 ± 0	0 (0-0)
1 hour post-infusion	13	10.3 ± 2.7	10.0 (6.5-16.5)
Mean change (primary analysis)*	15 [†]	8.9 ± 4.4	9.5 (0-16.5)

MCF = maximum clot firmness; mm = millimeter; ITT = intention-to-treat.
* p-value was <0.0001.
† The mean change was set to 0 for 2 subjects with missing MCF data.

300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320

Study 4003

Study 4003 was a multicenter, non-interventional, retrospective cohort study with a prospective observational 12-month follow-up period to investigate the safety and efficacy of RIASTAP for the treatment of acute bleeding events, routine prophylaxis, and perioperative hemostasis in subjects with congenital fibrinogen deficiency. A total of 22 subjects were enrolled. Eleven of the 22 subjects enrolled were 16 years of age or younger and 11 subjects were 18 years of age or older at the time of first recorded treatment, which was documented in the retrospective period prior to enrolment.

In the retrospective period, the hemostatic efficacy was rated by the investigator as “effective” for 97% of the acute bleeding events and for 97.5% of the bleeding events during surgery, and prophylactic use of RIASTAP was associated to a low median ABR of 1.43 bleeding events per year. The efficacy during the prospective period was consistent with that observed for the retrospective period: hemostatic efficacy was rated by the investigator as “effective” for 100% of bleeding events and during surgery, and the median ABR was also low at 1.26 bleeding events per year during routine prophylaxis with RIASTAP.

321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360

15 REFERENCES

1. Peyvandi F, Haertal S, Knaub S, *et al.* Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. *J Thromb Haemost* 2006; 4:1634-7.
2. Kreuz W, Meili E, Peter-Salonen K, *et al.* Pharmacokinetic properties of a pasteurized fibrinogen concentrate. *Transfusion and Apheresis Science* 2005; 32:239-46.
3. Colman R, Clowes A, George J, *et al.* Overview of Hemostasis. In: *Hemostasis and Thrombosis: Basic Principles and Clinical Practice* (5th ed.). Colman R, Clowes A, George J, Goldhaber S, Marder VJ (eds.). Lippincott Williams & Wilkins, Philadelphia 2006:11-14.
4. Kreuz W, Meili E, Peter-Salonen K, *et al.* Efficacy and tolerability of a pasteurized human fibrinogen concentrate in patients with congenital fibrinogen deficiency. *Transfusion and Apheresis Science* 2005; 32:247-253.
5. Fries D, Innerhofer P, Reif C, *et al.* The Effect of Fibrinogen Substitution on Reversal of Dilutional Coagulopathy: An In Vitro Model. *Anesth Analg* 2006; 102:347-351.
6. Kalina U, Stöhr HA, Bickhard H, *et. al.* Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. *Blood Coagulation and Fibrinolysis*. 2008; 19:777-783.

16 HOW SUPPLIED/STORAGE AND HANDLING

- RIASTAP is supplied in a single-dose vial.
- Each carton contains one vial of RIASTAP.
- Components are not made with natural rubber latex.
- RIASTAP contains no preservative.
- The actual potency of fibrinogen concentrate in milligram (mg) is stated on each RIASTAP vial label and carton.

The product presentation includes a package insert and the following component:

Table 4. How Supplied

Presentation	Carton NDC Number	Component
900-1300 mg	63833-891-51	RIASTAP in a single-dose vial (NDC 63833-891-90)

- When stored at temperatures of 2-8°C (36-46°F), RIASTAP is stable for the period indicated by the expiration date on the carton and vial label (up to 60 months). Do not use RIASTAP beyond the expiration date.
- Keep RIASTAP in its original carton until ready to use.
- Do not freeze. Protect from light.
- Discard partially used vials.

361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398

17 PATIENT COUNSELING INFORMATION

- **Allergic Reactions**

Inform patients of the early signs of allergic or hypersensitivity reactions to RIASTAP, including hives, chest tightness, wheezing, hypotension, and anaphylaxis. Advise them to notify their physician immediately if they experience any of these symptoms [see *Warnings and Precautions (5.1)*].

- **Thrombosis**

Inform patients that thrombosis with or without embolization has been reported with the use of RIASTAP. Any symptoms of thrombotic events such as unexplained pleuritic, chest and/or leg pain or edema, hemoptysis, dyspnea, tachypnea or unexplained neurologic symptoms should be reported to their physician immediately [see *Warnings and Precautions (5.2)*].

- **Transmissible Infectious Agents**

Inform patients that RIASTAP is made from human plasma (part of the blood) and may carry a risk of transmitting infectious agents e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Explain that the risk of transmitting an infection agent using RIASTAP has been reduced by screening plasma donors, testing the donated plasma for certain virus infections, and incorporating a process demonstrated to inactivate and/or remove certain viruses during manufacturing. Symptoms of possible virus infection include headache, fever, nausea, vomiting, weakness, malaise, diarrhea, or, in the case of hepatitis, jaundice [see *Warnings and Precautions (5.3)*].

Manufactured by:

CSL Behring GmbH
35041 Marburg Germany
US License No. 1765

Distributed by:

CSL Behring LLC
Kankakee, IL 60901 USA